Pure Global
NCT06231017

Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

A Single-arm, Open-label, Phase Ⅱ Clinical Trial of Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Colorectal Cancer
Drug/Device/Intervention
Adebrelimab + Cetuximab+ Chemotherapy
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The First Affiliated Hospital of Zhengzhou University
Location
Zhengzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Jan 19, 2024
End date
Jan 19, 2026
Enrollment
36 participants
Primary outcome

Objective response rate (ORR)

Summary

The purpose of this study is to observe and evaluate the efficacy and safety of adebrelimab
 plus cetuximab and chemotherapy for patients with RAS/BRAF wild-type unresectable liver
 metastases colorectal cancer.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06231017
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06231017 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital of Zhengzhou University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.